Free Trial

10 Best Small Cap Stocks to Buy Now - 9 of 10

 
 

Talphera (NASDAQ:TLPH)

Consensus Rating
Strong Buy
Rating Score
3.5
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$5.00 (880.4% Upside)

About Talphera

Talphera logoTalphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. More about Talphera
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/1/2025HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
1/28/2025RODMAN&RENSHAWUpgradeStrong-Buy
1/28/2025Rodman & RenshawInitiated CoverageBuy$4.00
1/21/2025HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
11/8/2024Maxim GroupUpgradeStrong-Buy
8/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00
5/6/2024Maxim GroupInitiated CoverageBuy$3.00
3/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00
1/22/2024HC WainwrightBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.00